{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:35:32Z","timestamp":1793216132345,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacadv.2026.103280","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:47:46Z","timestamp":1790358466000},"page":"103280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":false,"given":"Erin D.","family":"Michos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.103280_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib3","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2026.103280_bib4","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jjcc.2023.10.009","article-title":"Heart failure management guidelines: new recommendations and implementation","volume":"83","author":"Heidenreich","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacadv.2026.103280_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","article-title":"Heart failure with mid-range or mildly reduced ejection fraction","volume":"19","author":"Savarese","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2022.05.030","article-title":"From mid-range to mildly reduced ejection fraction heart failure: a call to treat","volume":"103","author":"Stolfo","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133182","article-title":"Pathophysiology of heart failure with preserved ejection fraction in overweight and obesity - clinical and treatment implications","volume":"430","author":"Rodrigues","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib10","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.hlc.2025.05.094","article-title":"iCARDIO alliance global implementation guidelines on heart failure 2025","volume":"34","author":"Chopra","year":"2025","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacadv.2026.103280_bib11","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2024.10","article-title":"Evidence for aldosterone antagonism in heart failure","volume":"10","author":"Sethi","year":"2024","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.jacadv.2026.103280_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib13","article-title":"Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF","volume":"13","author":"Sauer","year":"2026","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib14","doi-asserted-by":"crossref","first-page":"L10","DOI":"10.1093\/eurheartjsupp\/suac113","article-title":"The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?","volume":"24","author":"Docherty","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jacadv.2026.103280_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure","volume":"5","author":"Bassi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103280_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cardfail.2025.06.013","article-title":"The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology","volume":"32","author":"Lala","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib21","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/Valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.044785","article-title":"Contemporary guideline-directed medical therapy for heart failure in the United States: the EMPACE study","volume":"15","author":"Greene","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2026.103280_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jacc.2023.06.021","article-title":"Underutilization of mineralocorticoid antagonists in patients with heart failure with reduced ejection fraction","volume":"82","author":"Matsumoto","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists: rationale, evidence, and unanswered questions","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.002946","article-title":"Characterization of mineralocorticoid receptor antagonist therapy initiation in high-risk patients with heart failure","volume":"10","author":"Cooper","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacadv.2026.103280_bib28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/CIRCULATIONAHA.124.070228","article-title":"Rapid and intensive guideline-directed medical therapy for heart failure: 5 core principles","volume":"150","author":"Greene","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2025.0038","article-title":"Simultaneous or rapid initiation of combination therapy for heart failure with preserved ejection fraction","volume":"10","author":"Greene","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jchf.2023.07.014","article-title":"Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: systematic review and network meta-analysis","volume":"12","author":"Zafeiropoulos","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1725782","article-title":"Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacadv.2026.103280_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/ijms27020673","article-title":"Addressing unmet needs in heart failure with preserved ejection fraction: multi-omics approaches to therapeutic discovery","volume":"27","author":"Kim","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacadv.2026.103280_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011584","article-title":"Challenges related to out-of-pocket costs in heart failure management","volume":"18","author":"Rao","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pcad.2024.01.009","article-title":"New models for heart failure care delivery","volume":"82","author":"Xia","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacadv.2026.103280_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cardfail.2023.12.004","article-title":"Improving guideline-directed medical therapy for patients with heart failure with reduced ejection fraction: a review of implementation strategies","volume":"30","author":"Harrington","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib37","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.3390\/jcm13216398","article-title":"Finerenone: a third-generation MRA and its impact on cardiovascular health-insights from randomized controlled trials","volume":"13","author":"Sabina","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s43044-024-00586-z","article-title":"Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease","volume":"76","author":"Pradhan","year":"2024","journal-title":"Egypt Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib46","author":"Bayer"},{"key":"10.1016\/j.jacadv.2026.103280_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ndt\/gfab328","article-title":"Spironolactone and chlorthalidone\u2013old drugs, new uses\u2013but approach with caution","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacadv.2026.103280_bib48","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ejhf.3453","article-title":"The spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT-HFpEF): rationale and design","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib49","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.jacadv.2026.103280_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib54","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4081\/cardio.2026.100","article-title":"Beyond trial neutrality: treatment discontinuation and the hidden signal in SPIRIT-HF trial","volume":"4","author":"Copeland","year":"2026","journal-title":"Global Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib62","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.jacadv.2026.103280_bib63","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib64","first-page":"S1","article-title":"2025 HFAI guidelines for diagnosis and management of heart failure","volume":"3","author":"Chopra","year":"2025","journal-title":"Heart Fail J India"},{"key":"10.1016\/j.jacadv.2026.103280_bib66","first-page":"1857","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society 2025 guideline update for pharmacologic management of heart failure with nonreduced ejection fraction (LVEF > 40%)","volume":"41","author":"Virani","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib67","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacadv.2026.103280_bib68","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib69","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10741-025-10481-7","article-title":"Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum","volume":"30","author":"Shahid","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacadv.2026.103280_bib73","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20240676i","article-title":"\u201cThe Dynamic Duo\u201d: the new management of drug treatment for heart failure with mildly reduced or preserved ejection fraction","volume":"122","author":"Wolf","year":"2025","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib74","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib75","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib76","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib77","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib78","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib79","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.11904","article-title":"Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"314","author":"Cooper","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.103280_bib80","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ehjqcco\/qcy019","article-title":"A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure","volume":"4","author":"Nilsson","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jacadv.2026.103280_bib81","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/ejhf.3800","article-title":"Management of patients with heart failure at high risk of hyperkalaemia: the CARE-HK in HF registry","volume":"27","author":"Greene","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","article-title":"Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction","volume":"10","author":"Vardeny","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib83","first-page":"716","article-title":"Gynecomastia","volume":"85","author":"Dickson","year":"2012","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jacadv.2026.103280_bib84","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1524-6175.2004.3735.x","article-title":"Gynecomastia and antihypertensive therapy","volume":"6","author":"Mosenkis","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacadv.2026.103280_bib85","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1093\/eurheartj\/ehaf591","article-title":"Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions","volume":"46","author":"Inker","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib86","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.kint.2025.03.018","article-title":"Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis","volume":"108","author":"Navaneethan","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacadv.2026.103280_bib87","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial decline in glomerular filtration rate with finerenone in HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib89","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacc.2025.05.033","article-title":"Sodium-glucose cotransporter 2 inhibitor with and without an aldosterone antagonist for heart failure with preserved ejection fraction: the SOGALDI-PEF trial","volume":"86","author":"Ferreira","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib90","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib91","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-025-04037-3","article-title":"Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction","volume":"32","author":"Vaduganathan","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib92","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib93","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure and obesity. Reply","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib94","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103280_bib95","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib96","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3949\/ccjm.93a.25081","article-title":"FINEARTS-HF: improving outcomes in heart failure with preserved or mildly reduced ejection fraction","volume":"93","author":"Salahuddin","year":"2026","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.03.007","article-title":"Finerenone and NYHA functional class in heart failure: the FINEARTS-HF trial","volume":"14","author":"Ostrominski","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib98","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib99","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(25)01384-4","article-title":"Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention","volume":"406","author":"Ostrominski","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2026.103280_bib101","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib102","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103280_bib103","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1111\/dom.16371","article-title":"The interplay between heart failure and chronic kidney disease","volume":"27","author":"Lala","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2026.103280_bib104","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"Lofman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103280_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100705","article-title":"Heart failure with preserved ejection fraction with CKD: a narrative review of a multispecialty disorder","volume":"5","author":"Patel","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.jacadv.2026.103280_bib106","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s00392-022-02116-w","article-title":"Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial","volume":"112","author":"Ferreira","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib107","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103280_bib108","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.103280_bib109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nefroe.2020.06.006","article-title":"Burden and challenges of heart failure in patients with chronic kidney disease. A call to action","volume":"40","author":"Romero-Gonzalez","year":"2020","journal-title":"Nefrologia (Engl Ed)"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26007015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:24:50Z","timestamp":1793215490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26007015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2772963X26007015"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103280","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103280"}}